ESMO 2022

Consolidating data from prospective studies

Dose-dense therapy is beneficial for all patients

Roadmap for the adjuvant setting

Immuntherapy only for low risk patients?

Endocrine response in eBC

Dose-dense standard of care is the optimal care

Dose dense is better

Reduction of peripheral neuropathy with taxane therapy

My highlights of ESMO22

QoL and longterm toxicity

Long-term data on dose density therapy in chemotherapy

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

DD is the champion!

Simple and cheap surgical technique may impact survival in early breast cancer

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

I miei punti salienti di ESMO22

Schéma dose-dense bénéfique pour toutes les patientes

Il vincitore e’ il dose dense!!

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

Datele trialurilor se consolideata

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

Tailoring Adjuvant Therapy

Status update - adjuvant IO. Are TILs prognostic?

Unmeet needs and my wishes for 2022!

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

How to deal with the negative SERD data?

Survival benefit in endocrine sensitive patients

Exciting data, but Phase 3 studies are needed

The third in the bunch

Sacituzumab govitecan for everybody!

Survival benefit from SG in mBC

My highlights of ESMO22

New treatment option for heavily pre-treated patients with ER+ MBC

Update on biomarkers on ADCs of the DAISY trial

SG is a novel treatment option for HR+/HER2- disease

VEX has no place in chemotherapy of metastatic breast cancer

TROPiCS-02 highlights

Discontinued development

Interim analysis shows promising data on Abema in the 1st Line

Negative and yet positive?!

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

OS not significant, but re-assuring new data

CDK4/6i could be an option for selected ER+/HER2+ disease

ADC after ADC - is there any orientation?

HER2+ and still without chemotherapy

Another option for heavily pre-treated HR+ advanced breast cancer patients

More therapy options for patients with HR+, HER2+ disease

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

Sopravvivenza globale nello studio MONARCH3

I miei punti salienti di ESMO22

TROPiCS-02 highlights

Nouvelles données des analyses expolratoires dans l’étude DAISY

Survie globale pas encore significative statistiquement mais données rassurantes

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

Sacituzumab Govitecan: Un farmaco per tutte?

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

ADAURA Update - preventing relapse or just delaying it?

Long term follow-up of ADAURA trial

Osimertinib stays standard adjuvant

ADAURA revisited

INCREASE - to good to be true?

Osimertinib - curing or delaying relapse?

Neoadjuvant strategies for PD-L1 < 1 %

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Concurrent preoperative IO/CRT in early lung cancer

Window for treatment selection

Is OS really needed?

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Pollution and lung cancer - one mechanism revealed

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

ADAURA revisited

Osimertinib bleibt Standard adjuvant

Eine Plattform für "take the winner"-Strategie

Pollution et cancer du poumon - un mécanisme mis en évidence

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Langzeitdaten ADAURA

Osimertinib: una cura o ritarda la ripresa di malattia?

DFS matters!

Important data on borderline resectable patients

Can IO be discontinued?

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Sotorasib vs. Docetaxel in mKRAS G12C

If you don't look, vou don't find - once you found it, you'll treat it!

Poseidon and STK11/KEAP

Can we finally treat poor prognostic patients with immunotherapy?

A new step in treatment of KRAS G12C mutant NSCLC

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

Induction chemoimmunotherapy in borderline resectability?

Immunotherapy in unfit population? Perhaps...

Question about timing and duration of immunotherapy still unanswered

Is shorter immunotherapy equally effective and less physically demanding?

5-year update on 1st line chemoimmunotherapy

Atezolizumab better than vinorelbin in reduced performance status

Chemoimmunotherapy - improvement of survival after 5 years

DESTINY-Lung02 - better than the original?

Liquid biopsy monitoring in treatment decisions

Sotorasib - a new standard of care?

Preview on lung cancer highlights

New immunotherapy options for pts. ineligible to 1st line platinum therapy

Real-world data on Atezolizumab

HER2 - the next actionable mutation in lung cancer?

Pneumonitis and T-DXd

5-year data on survival under immunotherapy

One more brick in the KRAS G12C wall

Cemiplimab beyond progression?

Sotorasib: sweet and sour results

New therapy combination after progression on 1L osimertinib

5 years of chemoimmunotherapy: solid grounded

The journey at KRAS G12C continues

Emerging IO mono options in the first line

Die Reise bei KRAS G12C geht weiter

Neue Therapiekombination in der Resistenz nach Osimertinib

Neue Option der IO-Therapie in der Erstlinie

IO-IO neoadjuvant bei PD-L1 neg.

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Données de vie réelle avec l’atezolizumab

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Les études incontournables à l’ESMO 2022

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

Sotorasib vs. Docetaxel bei mKRAS G12C

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

Poseidon und STK11/KEAP

Chimio-immunothérapie - amélioration de la survie après 5 ans

Cemiplimab beyond progression?

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

Kann IO pausiert werden?

5-Jahresüberleben mit Immuntherapie

Atezo besser als Vino bei PS2-3

Resultados Agridulces de Sotorasib

Un mattone in piu' nel muro del KRAS G12C

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

Pneumonitis und T-DXd

Liquid Biopsy Monitoring zur Therapiesteuerung

5 Jahre Chemo-Immuntherapie: starker Effekt

Immunoterapia nella popolazione non fit: forse

New strategies in immunotherapy

Heterogenity in the genetic landscape - little progress in molecular alterations

Novel data and long-term efficacy of chemo-IO in mNSCLC

A positive study! With a question mark?

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

Adjuvant Immuntherapy in kidney cancer

Brief highlights about RCC & urothelial cancer from ESMO22

No value of IPI/Nivo in the adjuvant setting.

Immune-based peri-operative treatment in RCC: What went wrong?

Two negative studies question adjuvant approach in RCC

Exciting data for high-risk patients: is this the start of a new era?

Place of triplet therapy

More questions being raised

News in terms of adjuvant

New combo - triplet therapy for kidney cancer

Terapia triple para cancer renales

Inmunoterapia adyuvante en el cancer renales

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Shedding light on TKI/Checkpointinhibitor combinations

Therapy combinations in RCC - what is the role of triplet therapy?

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

Immunomodulation in combination with checkpointinhibiton

EV + Pembro with excellent response rates

Brief highlights about RCC & urothelial cancer from ESMO22

EV + pembrolizumab in cisplatin-ineligible patients

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Promising data, but beware of toxicity

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

Cabazitaxel better tolerated in elderly men

Radicals - ADT & Radiotherapy

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Optimizing cabazitaxel chemotherapy

In older vulnerable - less is more

ADCs - a possible therapeutic approach

Triplet therapy with darolutamide in prostate cancer

QoL data from ARASENS triplet therapy study mHRPC

Length of hormone therapy after radiation

Genetic testing before PARP therapy is useful

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

ADT + ENZA better choice than monotherapy

Biomarker data for better patients selection

Further evaluation of PSA correlates

IO + PARP without benefit in the allcomer situation

Update on the PROpel study

PSA at 8-months as a biomarker

Combination of olaparib leads to promising results

PSA efter 8 månader i PEACE-1 studien som biomarkör

Livskvalitetsuppföljning i ARASENS studien

Uppdatering i PROpel studien

Intimate partner violence in cancer patients

Novel approach von Biontech towards Cancer – game changing potential?!

TILs - Fashion is the eternal return of the old

New group of substances for rare diseases

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy

Addition of CPI to Radiochemotherapy in LA-HNSCC?